Piribedil
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Piribedil
Description:
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM) . Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
Adrenergic Receptor; Dopamine Receptor; Histone MethyltransferaseType:
Reference compoundRelated Pathways:
Epigenetics; GPCR/G Protein; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
Cancer; Endocrinology; Neurological DiseaseAssay Protocol:
https://www.medchemexpress.com/Piribedil.htmlPurity:
99.92Solubility:
DMSO : 33.33 mg/mL (ultrasonic)Smiles:
C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1Molecular Formula:
C16H18N4O2Molecular Weight:
298.34Precautions:
H302, H315, H319, H335References & Citations:
[1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16 (6) :1077-82. |[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α (2) adrenergic mechanisms. J Neural Transm (Vienna) . 2013 Jan;120 (1) :31-6. |[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17 (5) :887-901.|[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedIsoform:
D2 Receptor; D3 Receptor; α adrenergic receptorCAS Number:
[3605-01-4]
